Connect with us

Business

Share Now, formerly Car2Go, to end service in North America in February 2020 – CBC.ca

Published

 on


The car-share service Car2Go will shut down operations in North America early next year, including in Vancouver and Montreal. 

The German company, which recently merged with the car-share service DriveNow under the name Share Now, announced Wednesday that its last day of service will be Feb. 29, 2020.

As well as members in Vancouver and Montreal, the closure will affect riders in Chicago, New York City, Seattle and Washington, D.C.

In a statement, the company blamed the shutdown over the “volatile state of the global mobility landscape.”

It cited increased competition among car-share applications, rising operating costs and the lack of infrastructure to support new technology such as electric vehicle car share.

The company says it will also stop operating in London, Brussels and Florence due to low usage in those cities. The company will continue to operate in 18 cities in Europe.

“We deeply regret the inconvenience this decision causes,” the company wrote.

The company has recently suffered major blows in North America.

In October, it abruptly pulled out of Calgary, where it was the only car-share service in operation. It also exited Denver; Portland, Ore.; Austin, Texas; and Chicago. 

In May 2018, the company pulled out of Toronto, blaming new city rules that rendered its service “inoperable.”

More to come. 

Let’s block ads! (Why?)



Source link

Business

TD Bank Group reports Q1 profit up from year ago, tops expectations – Yahoo Canada Finance

Published

 on


GlobeNewswire

Ophthalmology Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030

Major companies in the ophthalmology drugs market include Novartis AG; F. Hoffmann-La Roche Ltd; Allergan Plc; Valeant Pharmaceuticals Intl Inc and Bayer AG. The global ophthalmology drugs market is expected to grow from $22.New York, Feb. 25, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Ophthalmology Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030” – https://www.reportlinker.com/p06027742/?utm_source=GNW 03 billion in 2020 to $24.42 billion in 2021 at a compound annual growth rate (CAGR) of 10.8%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $32.64 billion in 2025 at a CAGR of 8%.The ophthalmology drugs market consists of sales of ophthalmology drugs and related services by entities (organizations, sole traders and partnerships) that produce ophthalmology drugs to treat eye related diseases.The ophthalmology drugs industry includes establishments that produce pharmaceutical drugs to treat glaucoma diseases, anti- inflammatory and tear stimulating drugs under dry eye medications drugs, and other drugs for treating retinal disorders and allergies.Some of the major ophthalmic drugs include Eylea, Lucentis, Restasis, Vigamox, Azopt, and Lotemax. The ophthalmology drugs market is segmented into antiglaucoma drugs; dry eye medication; and other ophthalmological drugs (retinal disorders, anti-infectives/allergy).North America was the largest region in the global ophthalmology drugs market, accounting for 41% of the market in 2020.Asia Pacific was the second largest region accounting for 28% of the global ophthalmology drugs market.Africa was the smallest region in the global ophthalmology drugs market.Drug manufacturers are increasingly developing ophthalmic drugs with anti-inflammatory agents to ease patient treatment for dry eye syndrome.Anti-inflammatory drugs are widely used for the treatment of the inflammation produced by the dry eye syndrome, with the topical corticosteroid drops being the most common therapy.Corticosteroids can rapidly and effectively relieve the symptoms and signs of moderate or severe dry eye.However, prolonged usage of corticosteroids has seen to produce side effects that include risk of bacterial or fungal infection, elevated intraocular pressure and cataract formation.As a consequence, NSAIDs are increasingly being used as dry eye treatment instead of steroids to minimize the side effects. For instance, Aciex Therapeutics, a US-based pharmaceutical company, is developing NSAIDs which decrease ocular discomfort.Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients.These changes are related to data protection such as the European Union’s General Data Protection Regulation (GDPR), changes to drug approval procedures and other regulatory changes.For instance, according to a report by Ernst and Young in 2018, Fortune 500 companies are spending $7.8 billion to comply with GDPR regulations. The GDPR regulation is a EU law on data protection and privacy of individuals residing the European Union and the European Economic Area (EEA). It also regulates data anonymization thus maintaining integrity of data dealing with patients and other clinical trial studies. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts strain to investments relating to new product development, thereby affecting the growth of the ophthalmology drugs market.The expected rise in eye laser surgeries will contribute to the ophthalmology drugs market.Ophthalmology research has proved a link between laser eye surgeries and the prevalence of dry eye disorders.In an eye laser procedure, cutting of some nerves in the cornea leads to reduction in corneal sensitivity, in response to which, eyes may not sense the need for lubrication, causing the body to produce fewer tears.Dry eye is a common side effect after laser vision correction surgeries.It is estimated that almost half of the patients that undergo a laser surgery experience some degree of dry eye condition following the procedure.It is expected that the number of eye laser procedures will rise from 596,000 a year in 2015 to 720,000 a year in 2020.A rising number of people going for laser eye surgeries is expected to increase the demand for dry eye medications in the forecast period driving the ophthalmology drugs market.Read the full report: https://www.reportlinker.com/p06027742/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Day after doubling, GameStop is up another 67 per cent – CTV News

Published

 on


GameStop shares rallied 67% ahead of the opening bell Thursday, following another blockbuster day for the stock. On Wednesday, the gaming retailer’s stock closed nearly 104% higher.

Investors gained interest in the stock once again a few days after the company announced its chief financial officer would resign next month to help “accelerate GameStop’s transformation,” which could fuel investors who believe in the long-term value of the retailer and its ability to shift from relying on physical stores to an e-commerce sales model.

Trading of the stock was halted twice Wednesday and its trading volume was roughly three times higher than the five-day average for the stock, according to data provider Refinitiv.

Having déjà vu yet? The surge comes about a month after a wild GameStop trading frenzy caused its stock to jump around 1,600% in a matter of days, though it quickly fell from its highs around US$350 (Shares are set to open Thursday at around $150).

The late January surge was fuelled by individual retail investors, many from the Reddit page WallStreetBets, some of whom believed the GameStop was undervalued and others who wanted to squeeze hedge funds that had shorted the stock.

AMC, another “meme stock” involved in the trading frenzy last month, also jumped around 18% in premarket trading Thursday. As did Koss Corp., which manufactures headphones, soared 60% ahead of the opening bell. Clothing retailer Express also rose 15%.

CNN Business’ Clare Duffy contributed to this report

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Gold sees more downside price action amid rising bond yields – Kitco NEWS

Published

 on


Editor’s Note: With so much market volatility, stay on top of daily news! Get caught up in minutes with our speedy summary of today’s must-read news and expert opinions. Sign up here!

(Kitco News) – Gold futures prices are lower again in early U.S. trading Thursday. Rising government bond yields are at least short-term bearish for the precious metals markets as the benchmark U.S. Treasury note is presently yielding 1.45%, which is a one-year high. The shorter-term, chart based futures trader bears are having their way with the gold market at present. Silver is another story, as the metal still sees a near-term price uptrend in place and the silver bulls are much more resilient recently. April gold futures were last down $12.00 at $1,786.00 and March Comex silver was last up $0.096 at $27.97 an ounce.

Global stock markets were mostly higher overnight. U.S. stock indexes are pointed toward mixed openings when the New York day session begins. The discussion in the marketplace at present centers on global inflation prospects, with most traders reckoning inflation is up-ticking. The key question is how high will price inflation rise and will it become problematic. Government bond yields are trending up. Stock market bulls have taken note of the rising bond yields and are a bit worried about it. At least one big Wall Street investment bank is predicting a “commodity super-cycle” is just under way that will see raw commodity prices appreciate for quite some time to come. Many commodity futures markets such as the grains, crude oil and some softs have seen their prices hit multi-month and even multi-year highs this year.

Federal Reserve Chairman Jay Powell’s testimony to the U.S. Congress this week saw the central bank chief reiterate that U.S. money policy will remain very easy until U.S. employment has reached more normal levels coming out of the pandemic. This did work to assuage the stock index bulls a bit as prices have rebounded from early-week lows.

The key “outside markets” today see Nymex crude oil futures prices slightly up and trading around $63.30 a barrel. The U.S. dollar index is lower early today as the bulls have faded recently.

U.S. economic data due for release Thursday includes the weekly jobless claims report, the second estimate of four-quarter gross domestic product, durable goods orders, pending home sales and the Kansas City Fed manufacturing survey.

Live 24 hours gold chart [Kitco Inc.]

Technically, the February gold futures bears have the firm overall near-term technical advantage amid a six-week-old price downtrend in place on the daily chart. Bulls’ next upside price objective is to produce a close in April futures above solid resistance at this week’s high of $1,815.20. Bears’ next near-term downside price objective is pushing futures prices below solid technical support at the February low of $1,759.00. First resistance is seen at $1,800.00 and then at today’s high of $1,805.00. First support is seen at this week’s low of $1,778.60 and then at the November low of $1,771.30. Wyckoff’s Market Rating: 3.0

Live 24 hours silver chart [ Kitco Inc. ]

March silver futures bulls have the overall near-term technical advantage. Silver bulls’ next upside price objective is closing prices above solid technical resistance at the February high of $30.35 an ounce. The next downside price objective for the bears is closing prices below solid support at $26.00. First resistance is seen at the overnight high of $28.265 and then at this week’s high of $28.425. Next support is seen at this week’s low of $27.33 and then at $27.00. Wyckoff’s Market Rating: 6.5.

Let’s block ads! (Why?)



Source link

Continue Reading

Trending